Redeye leaves a short comment following the announcement of completed patient recruitment in Initiat...
Q3 – fullt fokus på patientrekrytering Diamyd släppte under gårdagen sin Q3-rapport för det brutna r...
Tidigare kvartals investeringar i marknadsföring återspeglas i lönsamhet Omsättningen i kvartalet up...
Redeye is positive about the last week’s strong order flow, which is highly important for the compan...
Redeye initiates coverage of Lifecare, an innovative medtech company offering a next-generation cont...
Mendus has provided an update on its development plans for its lead cancer vaccine, vididencel, prim...
Metacon växte intäkterna i Q1 och resultatet var negativt.
Redeye comments on the EU approval of MOB-015 and the new two-step approach to the EU launch.
With the Q1-report presented, it is clear that STENOCARE A/S (“STENOCARE” or the “Company”), has lai...
AVTECH has announced an extension of its Southwest agreement, which holds a value of SEK38m-52m over...
85% organic growth in Q2e and EBIT of SEK 61m H1 announced orders +52% y-o-y supports 2023e growth F...
Scandinavian Astor Group (”Astor Group” eller ”bolaget”) meddelade den 26 juni att dotterbolaget Mar...
Redeye comments on Lipigon's licensing agreement with Leaderna for Greater China.
Q2e: sales SEK 245m, EBITA 6.8%, EPS SEK 0.57 Expect order book realisation to continue, outlook pro...
Taaleri announced after market close that it has exited Forest Fund III with IRR of around 10%.
Redeye comments on Smart Eye's breakthrough deal for AIS with Linde.
Samtrygg genomför nu en företrädesemission med teckningsperiod 21 juni - 7 juli.
Ecoclime uppvisade stark tillväxt i Q1 om 38% men resultatet var fortsatt svagt.
Redeye endorses Qlife’s new strategy, which will allow life science companies to use Qlife’s platfor...
Marknaden är oförändrad sedan Q1-annonseringen – anpassar kostnadskostymen För att hantera de uppskj...
